ORBITA-2
Research type
Research Study
Full title
ORBITA-2: A placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina
IRAS ID
242451
Contact name
Alexandra Nowbar
Contact email
Sponsor organisation
Joint Research Compliance Office, Imperial College London
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Narrowing of the coronary arteries can cause chest pain on physical activitiy. This is called angina. Angioplasty of the narrowings is often carried out to relieve this. In the first blinded placebo-controlled trial of this therapy (ORBITA) we found that symptoms were no better than with intensive medical therapy (tablets). In this study we will determine how much difference angioplasty makes to symptoms without background medical therapy using the same scientific blinding of the patient and subsequent healthcare staff. Patients with single and multivessel coronary disease will be eligible. After the 12 week blinded phase, all patients will be unblinded and patients who had undergone placebo will be offered the active therapy.
REC name
London - Central Research Ethics Committee
REC reference
18/LO/1203
Date of REC Opinion
31 Aug 2018
REC opinion
Further Information Favourable Opinion